Back to drug

The Drug-Induced Respiratory Disease Website

Or 'ILD'. (Fr: PnP subaiguë). A.k.a. pulmonary infiltrates. Generally bilateral and symmetrical. Gradual onset. Consistent with but not specific for an NSIP-c pattern on pathology. Less- dense, severe, acute and diffuse than pattern Ia. Lacks the features of ARDS that may accompany pattern Ia. Can be in the form of disseminated linear, reticulonodular, miliary or patchy opacities. BAL is indicated to separate this pattern from PIE (Ic) or DAH (IIIa). Acute chest pain can be at the forefront. A search for microorganisms including Pneumocystis (stains, PCR) is indicated. On pathology (although not many cases undergo a confirmatory lung biopsy), there is interstitial inflammation and a more or less dense cellular interstitial cellular infiltrate (NSIP-c). Fibrosis, alveolar edema and/or a reactive epithelium denote those cases resulting from with antineoplastic chemotherapy agents. The frontier between patterns Ia and I b can be difficult to draw, so please check drugs under both Ia and Ib. Patients may quickly shift from pattern Ib to Ia particularly if the the causal drug is inappropriately continued. Prompt withdrawal must be considered, underlying disease permitting, and can be therapeutic.

Publications

Jasielec JK, Larson RA

Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Feb 20;34;e46-8 — 2016 Feb 20 — e46-8

Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P

Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

American journal of respiratory and critical care medicine 2007 Oct 15;176;814-8 — 2007 Oct 15 — 814-8

Radaelli F, Bramanti S, Fantini NN, Fabio G, Greco I, Lambertenghi-Deliliers G

Dasatinib-related alveolar pneumonia responsive to corticosteroids.

Leukemia & lymphoma 2006 Jun;47;1180-1 — 2006 Jun — 1180-1